

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1.-13. (canceled)

14. (currently amended) A DNA transfer vctor ~~containing a~~ comprising a nucleotide sequence ~~coding for a fragment, wherein said sequence is~~ selected from the group consisting of SEQ ID [[N.]] NO: 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, and 14.

15. (currently amended) ~~A~~ The DNA transfer vector according to claim 14, ~~which~~ wherein said vector is a plasmid.

16. (currently amended) The DNA transfer vector of claim 15, further ~~containing~~ comprising a transcription promotor.

17. (currently amended) The DNA transfer vector of claim 16, wherein the transcription promotor is CMV.

18. (currently amended) The DNA transfer vector of claim 15, further ~~containing~~ comprising 4 CpG motifs.

19. (currently amended) The DNA transfer vector of claim 18, further ~~containing~~ comprising 8 CpG motifs.

20. (currently amended) A ~~Pharmaceutical~~ pharmaceutical composition ~~containing~~ comprising a DNA transfer vector according

to claim 14 in admixture with pharmaceutically acceptable vehicles and excipients.

21. (currently amended) The pharmaceutical composition according to claim [[7]] 20, which wherein said composition is in a form for parenteral administration.

22. (currently amended) The pharmaceutical composition of claim [[8]] 21, which wherein said composition is in the form of an injectable solution.

23. (withdrawn and currently amended) A combined pharmaceutical preparation ~~containing~~ comprising at least two different DNA transfer vectors according to claim 14, for simultaneous, sequential or separate therapeutic use.

24. (withdrawn and currently amended) ~~A~~ The combined preparation according to claim 23, ~~which~~ wherein said preparation is in a form suitable for DNA vaccination.

25. (withdrawn and currently amended) A method for the preventive or therapeutical treatment of a subject at risk of developing ~~pi~~ p185neu positive tumours, or of a subject having primary tumours, metastasis or relapses of p185neu-expressing tumours, comprising administering to said subject an ~~affective~~ effective amount of a DNA transfer vector according to claim 14.

26. (withdrawn) The use according to claim 25, for the preparation of a DNA vaccine.